XENCOR INC (XNCR)
US98401F1057 - Common Stock
July 19th Options Now Available For Xencor (XNCR)
XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024
XNCR stock results show that Xencor missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xencor (NASDAQ:XNCR) just reported results for the first quarter of 2024.Xencor...
Xencor Reports First Quarter 2024 Financial Results
XNCR Makes Bullish Cross Above Critical Moving Average
Xencor Becomes Oversold (XNCR)
Xencor Appoints Bart Cornelissen as Chief Financial Officer
XNCR Crosses Below Key Moving Average Level
Xencor to Present at Upcoming Investor Conferences
Xencor stock slips as Piper cuts on patient death in study
Xencor (XNCR) stock fell as Piper Sandler downgraded the stock citing a death in a mid-stage trial for its prostate cancer drug, vudalimab. Read more here.
(NASDAQ:XNCR)
Xencor's Q4 results disappoint as GAAP EPS and revenue fall short of expectations, indicating potential financial challenges for the company.
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor (XNCR) Shares Cross Above 200 DMA
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
Xencor stock falls after royalty sale (NASDAQ:XNCR)
Xencor (XNCR) shares drop as the company sells ownership rights to Ultomiris and Monjuvi treatments, receiving $215M from OMERS' Life Sciences unit. Read more here.
Xencor GAAP EPS of -$0.40 beats by $0.31, revenue of $59.16M beats by $29.13M (NASDAQ:XNCR)
Xencor beats expectations in Q3 with a GAAP EPS of -$0.40 and revenue of $59.16M.
Xencor Reports Third Quarter 2023 Financial Results
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
Xencor finance chief to step down (NASDAQ:XNCR)
Xencor, a biopharmaceutical company, announces retirement of CFO John Kuch after a long career, but he will assist in finding a replacement.
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
Xencor Enters Oversold Territory (XNCR)
Xencor to Present Multiple Posters at the SITC Annual Meeting
